Acid Bacteria and Bifidobacteria as Vehicles of DNA Microbial Biosensors
Greg
May 24, 2021
Fluorescent Lactic Acid Micro organism and Bifidobacteria as Automobiles of DNA Microbial Biosensors
Administration and quantification of effector molecules comparable to heavy metals, toxins or totally different objective molecules is of good biotechnological, social and monetary curiosity. Microorganisms have regulatory proteins that acknowledge and modify the gene expression inside the presence or absence of these compounds (effector molecules) through binding to gene sequences. The affiliation of these recognizing gene sequences to reporter genes will allow the detection of effector molecules of curiosity with extreme sensitivity.
As quickly as investigators have these two elements-recognizing gene sequences and reporter genes that emit signals-we need an acceptable vehicle to introduce every elements. Proper right here, we suggest lactic acid micro organism (LAB) and bifidobacteria as promising service microorganisms for these molecular biosensors. Utilizing fluorescent proteins along with food-grade vectors and clustered repeatedly interspaced temporary palindromic repeats (CRISPR) are indispensable devices for introducing biosensors into these microorganisms. Utilizing these LAB and bifidobacteria could be of specific curiosity for studying the intestinal setting or totally different superior ecosystems.
The great variety of species tailor-made to many environments, along with the chance of creating use of a variety of protocols for his or her transformation with recognizing gene sequences and reporter genes are considerable advantages. Lastly, an effort must be made to go looking out recognizable gene sequences.

phylowidget
DNAAF5 Polyclonal Antibody |
A58814-050 |
EpiGentek |
50 ul |
EUR 302.5 |
DNAAF5 Polyclonal Antibody |
A58814-100 |
EpiGentek |
100 ul |
EUR 423.5 |
DNAAF5 Polyclonal Antibody |
A58814 |
EpiGentek |
-
EUR 684.66
-
EUR 117.70
-
EUR 302.50
-
EUR 423.50
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
DNAAF5 Antibody, HRP conjugated |
1-CSB-PA771471LB01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against DNAAF5. Recognizes DNAAF5 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
DNAAF5 Antibody, FITC conjugated |
1-CSB-PA771471LC01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against DNAAF5. Recognizes DNAAF5 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
DNAAF5 Antibody, Biotin conjugated |
1-CSB-PA771471LD01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against DNAAF5. Recognizes DNAAF5 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
DNAAF5 Polyclonal Antibody, Biotin Conjugated |
A58815-050 |
EpiGentek |
50 ul |
EUR 302.5 |
DNAAF5 Polyclonal Antibody, Biotin Conjugated |
A58815-100 |
EpiGentek |
100 ul |
EUR 423.5 |
DNAAF5 Polyclonal Antibody, FITC Conjugated |
A58816-050 |
EpiGentek |
50 ul |
EUR 302.5 |
DNAAF5 Polyclonal Antibody, FITC Conjugated |
A58816-100 |
EpiGentek |
100 ul |
EUR 423.5 |
DNAAF5 Polyclonal Antibody, HRP Conjugated |
A58817-050 |
EpiGentek |
50 ul |
EUR 302.5 |
DNAAF5 Polyclonal Antibody, HRP Conjugated |
A58817-100 |
EpiGentek |
100 ul |
EUR 423.5 |
DNAAF5 Polyclonal Antibody, Biotin Conjugated |
A58815 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
DNAAF5 Polyclonal Antibody, FITC Conjugated |
A58816 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
DNAAF5 Polyclonal Antibody, HRP Conjugated |
A58817 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
Human Dynein Assembly Factor 5, Axonemal / HEATR2 (DNAAF5) ELISA Kit |
abx387761-96tests |
Abbexa |
96 tests |
EUR 1093.2 |
|
ASAP1 antibody Antibody |
DF8746 |
Affbiotech |
200ul |
EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
LSMab09882 |
Lifescience Market |
100 ug |
EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
F54788-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
F54788-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 379 |
Antibody |
A1360-500 |
Biovision |
each |
Ask for price |
Anti-Glycolipid Antibody (AGA) Antibody |
20-abx004855 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx008109 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx123734 |
Abbexa |
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx014333 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx033330-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx033330-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Anti-Glycolipid Antibody (AGA) Antibody |
abx036399-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319900 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319901 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319905 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319913 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
abx230204-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx324434 |
Abbexa |
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx311665 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx234901-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
Anti-Anti-SEPT6 antibody antibody |
STJ11100949 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
STJ111369 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT4 Antibody antibody |
STJ112276 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-SEPT5 Antibody antibody |
STJ114819 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT7 Antibody antibody |
STJ116214 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
STJ117206 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT12 Antibody antibody |
STJ117759 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT7 Antibody antibody |
STJ28963 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT5 Antibody antibody |
STJ25477 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
STJ25479 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT1 antibody antibody |
STJ119580 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
CLCN5 Antibody / CIC-5 antibody |
RQ6462 |
NSJ Bioreagents |
100ug |
EUR 419 |
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
48169-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
48169-50ul |
SAB |
50ul |
EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
065-A-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
065-A-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
Antibody Pair to ApoA-V antibody |
10R-1876 |
Fitzgerald |
100 ul |
EUR 781.2 |
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103034 |
Abbexa |
-
EUR 543.60
-
EUR 159.60
-
EUR 1562.40
-
EUR 744.00
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103035 |
Abbexa |
-
EUR 560.40
-
EUR 159.60
-
EUR 1612.80
-
EUR 760.80
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103036 |
Abbexa |
-
EUR 577.20
-
EUR 159.60
-
EUR 1696.80
-
EUR 794.40
-
EUR 427.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
abx023924-1mg |
Abbexa |
1 mg |
EUR 1446 |
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319902 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319903 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319904 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319906 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319907 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319908 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319914 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319915 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319916 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319929 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319930 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319931 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
20-abx311666 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
20-abx311667 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
20-abx311668 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
abx233571-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
abx411057-50ug |
Abbexa |
50 ug |
EUR 710.4 |
|
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
AMM06679G |
Leading Biology |
0.05mg |
EUR 633.6 |
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
Goat anti- human Antibody^Polyclonal antibody |
LSMab09896 |
Lifescience Market |
100 ug |
EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
SPC-692D |
Stressmarq |
0.1mg |
EUR 424.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A390 |
Stressmarq |
0.1mg |
EUR 481.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A488 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A565 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A594 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A633 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A655 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A680 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A700 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-ALP |
Stressmarq |
0.1mg |
EUR 472.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-APC |
Stressmarq |
0.1mg |
EUR 478.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-APCCY7 |
Stressmarq |
0.1mg |
EUR 565.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-BI |
Stressmarq |
0.1mg |
EUR 475.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY350 |
Stressmarq |
0.1mg |
EUR 496.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY405 |
Stressmarq |
0.1mg |
EUR 483.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY488 |
Stressmarq |
0.1mg |
EUR 471.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY594 |
Stressmarq |
0.1mg |
EUR 474 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY633 |
Stressmarq |
0.1mg |
EUR 468 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-FITC |
Stressmarq |
0.1mg |
EUR 470.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-HRP |
Stressmarq |
0.1mg |
EUR 465.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-P594 |
Stressmarq |
0.1mg |
EUR 488.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-PCP |
Stressmarq |
0.1mg |
EUR 478.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-RPE |
Stressmarq |
0.1mg |
EUR 476.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-STR |
Stressmarq |
0.1mg |
EUR 477.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
Antibody for Human alpha Tubulin Antibody |
SPC-692S |
Stressmarq |
0.012mg |
EUR 78 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Lambda Light Chain Antibody / Lambda Antibody |
R20161-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20161BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20161SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
R20179-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20179BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20179SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
RQ4975 |
NSJ Bioreagents |
100ul |
EUR 419 |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Irregular Homocysteine Metabolism: An Notion of Alzheimer’s Sickness from DNA Methylation
Alzheimer’s sickness (AD) is a persistent neurodegenerative sickness inside the central nervous system that has superior pathogenesis inside the aged. The current analysis focuses on the epigenetic mechanisms of AD, in response to the most recent findings. The best-characterized chromatin modifications in epigenetic mechanisms is DNA methylation. Extraordinarily replicable data reveals that AD incidence is often accompanied by methylation diploma changes of the AD-related gene.
Homocysteine (Hcy) is simply not solely an intermediate product of one-carbon metabolism however as well as an important neutral hazard concern of AD; it could probably affect the cognitive carry out of the thoughts by altering the one-carbon metabolism and interfering with the DNA methylation course of, resulting in cerebrovascular sickness.
Often, Hcy may be an environmental concern that impacts AD by means of the DNA methylation pathway with a group of changes in AD-related substance. This analysis will take into consideration the relation between DNA methylation and Hcy and try to find out their rule inside the pathophysiology of AD.
TET is focused for proteasomal degradation by the PHD-pVHL pathway to scale back DNA hydroxymethylation
Hypoxia-inducible elements are heterodimeric transcription elements that play an necessary place in a cell’s functionality to adapt to low oxygen. The von-Hippel Lindau tumor suppressor (pVHL), acts as a grasp regulator of HIF train, and its specializing in of prolyl hydroxylated HIF-α for proteasomal degradation beneath normoxia is taken into account a big mechanism for pVHL tumor suppression and cellular response to oxygen.
Whether or not or not pVHL regulates totally different targets by the identical mechanism is actually unknown. Proper right here, we decide TET2/Three as novel targets of pVHL. pVHL induces proteasomal degradation of TET2/3, resulting in decreased worldwide 5-hydroxymethylcytosine ranges.
Conserved proline residues contained in the LAP/LAP-like motifs of these two proteins are hydroxylated by the prolyl hydroxylase enzymes (PHD2/EGLN1 and PHD3/EGLN3), which is prerequisite for pVHL-mediated degradation. Using zebrafish as a model, we determined that worldwide 5-hydroxymethylcytosine ranges are enhanced in vhl-null, egln1a/b-double null and egln3-null embryos.
Subsequently, we reveal a novel carry out for the PHD-pVHL pathway in regulating TET protein stability and train. These data lengthen our understanding of how TET proteins are regulated and provide new notion into the mechanisms of pVHL in tumor suppression.
Degree-of-care DNA testing by routinely and sequentially performing extraction, amplification and identification in a closed-type cassette
- Nucleic acid detection is important for scientific diagnostics; nonetheless, it is tough to hold out genetic testing on the point-of-care due to the tedious steps involved in DNA extraction and the prospect of cross-contamination from amplicons.
- To comprehend a fully-automated and contamination-free nucleic acid detection, we propose a closed-type cassette system which permits the following steps to be operated routinely and sequentially: sample preparation primarily based totally on magnetic beads, objective amplification using multiplex polymerase chain response, and colorimetric detection of amplicons using a serial invasive response coupled with the aggregation of gold nanoparticle probes.
- The cassette was designed to be spherical and closed, and 10 targets in a sample is perhaps concurrently detected by the naked eye or using a spectrophotometer inside the system.
- In addition to, a cassette-driven system was fabricated to modify reagents between wells, to manage the temperature of each response, and to sense the colour inside the detection wells. The cassette system was delicate adequate to detect 10 genotypes at 5 single nucleotide polymorphism web sites related to the anticoagulant’s utilization, via using a 0.5 µL blood sample.
- The accuracy of the system was evaluated by detecting 12 total blood samples, and the outcomes obtained have been in line with these obtained using pyrosequencing. The cassette is airtight and the complete system is totally computerized; the one information operation is the addition of the sample to the cassette, performing point-of-care genetic testing in a sample-in/answer-out means.